Abstract
Sixteen Ugandan patients who had advanced malignant melanoma were treated with a combination of BCNU and vincristine, but only two transient objective tumor responses (13%) were observed. Drug toxicity at the doses used in the present study did not result in clinical complications, and no drug‐related deaths were seen. Leukopenia was observed in all patients but the WBC never fell to less than 1500/mm3. Platelet counts were consistently above 100,000/mm3. The results of therapy with the BCNU‐vincristine combination for advanced malignant melanoma, which have been promising in the United States, have been disappointing in Ugandan patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 337-341 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 31 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1973 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda'. Together they form a unique fingerprint.
Cite this
Primack, A., Dhru, D., Kiryabwire, J. W. M., & Vogel, C. L. (1973). Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda. Cancer, 31(2), 337-341. https://doi.org/10.1002/1097-0142(197302)31:2<337::AID-CNCR2820310211>3.0.CO;2-7